CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical to Host Conference Call to Provide First Quarter 2017 Business Update

19 Apr 2017, 08:00
Regulatory information
On 26 April 2017, at 08:00 CET, Hansa Medical will publish its report for the first quarter of 2017. All interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 14:00 CET. The event will be hosted by Hansa Medical’s CEO and President, Göran Arvidson, and the presentation will be held in English.

Slides used in the presentation will be live on the company’s website during the call under Events & Webcast and will be made available after the call as well. To participate in the telephone conference, please call:

SE: +46 (0) 856 642 693
UK: +44 (0) 2030 089 803
US: +1 855 753 2236

A link to audio cast can be found on the Hansa Medical website under Events & Webcasts or here: https://tv.streamfabriken.com/hansa-medical-q1-2017 

Files

For further information, please contact:
Hansa Medical AB (Publ)
Emanuel Björne, Vice President Business Development and Investor Relations
Mobil: +46707175477
E-mail: emanuel.bjorne@hansamedical.com

Göran Arvidson, President and CEO
Mobile: +4670633 3042
E-mail: goran.arvidson@hansamedical.com

Cord Communications, Stockholm
Mikael Widell
Mobile: +46 70 311 9960

Lars Wahlström
Mobile: +46 73 434 0771

FTI Consulting, London
Julia Phillips / Stephanie Cuthbert / Hanna Skeppner: +44 203 727 1000

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project IdeS is a proprietary antibody- degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in
other solid organ transplants and a wide range of acute autoimmune and oncology indications. The company also has a strong pipeline of preclinical assets that will provide a second wave of potential drugs as well as rights to royalties from the sales
of an innovative diagnostic assay for prediction of severe sepsis at emergency departments. Hansa Medical is based in Lund, Sweden, its shares share (ticker: HMED) are listed on Nasdaq Stockholm.